Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Astellas Stays Ahead of Daiichi Sankyo In AML With CHMP Nod For Xospata

Mon, 09/23/2019 - 7:41am

A positive opinion for its FLT3 inhibitor for acute myeloid leukemia gives Astellas a further advantage over its Japanese competitor's...

      Related Stories 

Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention

Fri, 09/20/2019 - 1:21pm

UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and...

      Related Stories 

Pipeline Watch: Phase II Starts In Hearing Loss, Type 1 Diabetes

Fri, 09/20/2019 - 7:44am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Gene Profiling Identifies Drugs For Childhood Cancers But Access A Problem

Fri, 09/20/2019 - 7:23am

Lack of infrastructure for identifying mutations and access routes is holding back use of targeted medicines in children with cancer

      Related Stories 

Emmaus Fumes After EMA Rejects Sickle Cell Drug Again

Fri, 09/20/2019 - 5:08am

The US firm has withdrawn its submission to get EU approval for Xyndari. After being turned down by the CHMP...

      Related Stories 

Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN

Thu, 09/19/2019 - 8:16pm

Following a major setback in another indication earlier this year, ASLAN’s lead asset is now seen as a potential new...

      Related Stories 

ARIBIO Counts On Multi-Modal Drug For Alzheimer's And Vascular Dementia

Thu, 09/19/2019 - 5:51pm

ARIBIO CEO tells Scrip how the South Korean biotech is aiming to develop a multi-modal drug for both Alzheimer’s disease...

      Related Stories 

What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot

Thu, 09/19/2019 - 3:26pm

China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets...

      Related Stories 

Boundless Bio Launches With $46m And Novel Oncology Focus On Extrachromosomal DNA

Thu, 09/19/2019 - 2:49pm

Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but...

      Related Stories 

J&J's Erleada Approved By FDA In New Prostate Cancer Indication

Thu, 09/19/2019 - 9:39am

Erleada was approved for treatment of metastatic castration-sensitive prostate cancer (mCSPC), strengthening its position versus generic Zytiga and Pfizer/Astellas's Xtandi.

      Related Stories 

Themis CEO: Chikungunya Vaccine Could Be Approved In Two Years

Thu, 09/19/2019 - 9:34am

Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for...

      Related Stories 

Ten Strategies For Success In Antibody-Drug Conjugate Development

Thu, 09/19/2019 - 8:00am

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a...

      Related Stories 

Prescription Influencer Shifts In India: Is Pharma Geared Up?

Wed, 09/18/2019 - 6:01pm

With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a...

      Related Stories 

Pages